Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
Aged
Blood Pressure
Cardiovascular Diseases
/ complications
Diabetes Mellitus, Type 2
/ complications
Drug Combinations
Female
Humans
Hypoglycemic Agents
/ administration & dosage
Insulin, Long-Acting
/ administration & dosage
Liraglutide
/ administration & dosage
Male
Middle Aged
Risk Factors
Waist Circumference
basal insulin
cardiovascular disease
liraglutide
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
19
11
2018
revised:
15
02
2019
accepted:
16
02
2019
pubmed:
21
2
2019
medline:
30
5
2020
entrez:
21
2
2019
Statut:
ppublish
Résumé
In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal-bolus therapy) trials, grouped by sex, age (<65 years, ≥65 years) and diabetes duration (<10 years, ≥10 years). Treatment contrasts were in favour of IDegLira in many subgroups for changes from baseline in glycated haemoblogin (DUAL II, DUAL V), body weight (all three trials), systolic blood pressure (BP; all three trials), HDL cholesterol (DUAL VII) and LDL cholesterol (DUAL II, DUAL V). Higher heart rates were seen with IDegLira versus comparators (all three trials) plus significantly higher diastolic BP in men (DUAL V). Differences in treatment effect were seen between sexes in waist circumference (DUAL II), systolic BP (DUAL II, DUAL V) and triglycerides (DUAL VII), and between diabetes durations in LDL cholesterol (DUAL V). In conclusion, IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal-bolus therapy after 26 weeks of treatment.
Identifiants
pubmed: 30785655
doi: 10.1111/dom.13675
pmc: PMC6593827
doi:
Substances chimiques
Drug Combinations
0
Hypoglycemic Agents
0
Insulin, Long-Acting
0
insulin degludec
54Q18076QB
Liraglutide
839I73S42A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1506-1512Informations de copyright
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Lancet. 2018 Oct 27;392(10157):1519-1529
pubmed: 30291013
Diabetes Care. 2014 Nov;37(11):2926-33
pubmed: 25114296
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Hypertension. 2014 Oct;64(4):731-7
pubmed: 24980665
Cell Metab. 2016 Jul 12;24(1):15-30
pubmed: 27345422
JAMA. 2016 Mar 1;315(9):898-907
pubmed: 26934259
Diabetes Obes Metab. 2019 Jun;21(6):1506-1512
pubmed: 30785655
Diabetes Care. 2018 May;41(5):1009-1016
pubmed: 29483185
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
N Engl J Med. 2015 Dec 3;373(23):2247-57
pubmed: 26630143
N Engl J Med. 2017 Sep 28;377(13):1228-1239
pubmed: 28910237
N Engl J Med. 2017 Aug 24;377(8):723-732
pubmed: 28605603
Diabetes Care. 2017 Jan;40(1):117-124
pubmed: 27797930